Therefore, we selected these two cancer types, which showed the best response, to explore the correlation between TRK-950 efficacy and CAPRIN-1 expression, as well as the characterization of the immunologic events associated with the treatment of TRK-950. The gene discussed is CAPRIN1; the disease is cancer.